tradingkey.logo
tradingkey.logo
Suchen

Precigen Inc

PGEN
Zur Watchlist hinzufügen
5.220USD
-0.030-0.57%
Handelsschluss 07/01, 16:00ETKurse um 15 Minuten verzögert
1.86BMarktkapitalisierung
VerlustKGV TTM

mehr Informationen über Precigen Inc Unternehmen

Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.

Precigen Inc Informationen

BörsenkürzelPGEN
Name des UnternehmensPrecigen Inc
IPO-datumAug 08, 2013
CEOSabzevari (Helen)
Anzahl der mitarbeiter143
WertpapierartOrdinary Share
GeschäftsjahresendeAug 08
Addresse20374 Seneca Meadows Parkway
StadtGERMANTOWN
BörseNASDAQ OMX - NASDAQ BASIC
LandUnited States of America
Postleitzahl20876
Telefon13015569900
Websitehttps://precigen.com/
BörsenkürzelPGEN
IPO-datumAug 08, 2013
CEOSabzevari (Helen)

Führungskräfte von Precigen Inc

Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Helen Sabzevari, Ph.D.
Dr. Helen Sabzevari, Ph.D.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
3.77M
+3.47%
Mr. Fred Hassan
Mr. Fred Hassan
Independent Director
Independent Director
1.24M
+7.22%
Mr. Steven R. Frank
Mr. Steven R. Frank
Independent Director
Independent Director
1.23M
+7.02%
Mr. James S. (Jim) Turley
Mr. James S. (Jim) Turley
Lead Independent Director
Lead Independent Director
685.42K
+13.08%
Ms. Vinita D. Gupta
Ms. Vinita D. Gupta
Independent Director
Independent Director
669.03K
+13.42%
Ms. Nancy Howell Agee
Ms. Nancy Howell Agee
Independent Director
Independent Director
305.78K
+28.76%
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Mr. Jeffrey B. (Jeff) Kindler, Esq.
Independent Director
Independent Director
202.10K
+45.27%
Mr. Phil Tennant
Mr. Phil Tennant
Chief Commercial Officer
Chief Commercial Officer
139.37K
+23.12%
Mr. Randal Joe Kirk
Mr. Randal Joe Kirk
Executive Chairman of the Board
Executive Chairman of the Board
--
--
Mr. Donald P. Lehr
Mr. Donald P. Lehr
Chief Legal Officer, Corporate Secretary
Chief Legal Officer, Corporate Secretary
--
--
Mehr Anzeigen
Name
Name/Position
Position
Aktienbesitz
Veränderung
Dr. Helen Sabzevari, Ph.D.
Dr. Helen Sabzevari, Ph.D.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
President, Chief Executive Officer, Director, President of PGEN Therapeutics, Inc.
3.77M
+3.47%
Mr. Fred Hassan
Mr. Fred Hassan
Independent Director
Independent Director
1.24M
+7.22%
Mr. Steven R. Frank
Mr. Steven R. Frank
Independent Director
Independent Director
1.23M
+7.02%
Mr. James S. (Jim) Turley
Mr. James S. (Jim) Turley
Lead Independent Director
Lead Independent Director
685.42K
+13.08%
Ms. Vinita D. Gupta
Ms. Vinita D. Gupta
Independent Director
Independent Director
669.03K
+13.42%
Ms. Nancy Howell Agee
Ms. Nancy Howell Agee
Independent Director
Independent Director
305.78K
+28.76%

Häufig gestellte Fragen

Wer sind die fünf größten Anteilseigner von Precigen Inc?

Die fünf größten Anteilseigner von Precigen Inc sind: Dr. Helen Sabzevari, Ph.D.

Wie viele Institutionen halten Anteile an Precigen Inc (PGEN)?

Mit Stand vom 2026Q1 halten 355 Institutionen Anteile an Precigen Inc, mit einem Gesamtmarktwert von etwa 270.08M, was 75.82% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 16216262.00 gestiegen.

Was ist die größte Einnahmequelle von Precigen Inc?

Am 2026Q1 erzielte das Geschäft mit Product für Precigen Inc den höchsten Umsatz in Höhe von 3.98M, was 41.05% des Gesamtumsatzes entspricht.